Abstract: The invention relates to polypeptides, in particular to penta- and hexapeptides, characterized by the general formula I: ##STR1## or a functional derivative thereof, wherein Z represents hydrogen or NH.sub.2,ALK.sub.1 represents an alkylene or alkylidene group having 1-6 carbon atoms,ALK.sub.2 represents an alkylidene group having 1-6 carbon atoms,Met.sub.x represents the aminoacid radical Met, Met(O) or Met(O.sub.2) andQ represents the aminoacid radical Lys or Arg, with the proviso that one of the aminoacid radicals Q and the C-terminal Phe is in the D-configuration and the other has the L-configuration.

Abstract: The present invention is dealing with a pharmaceutical composition containing a peptide of the formula:R.sub.1 -L-Tyr-L-Val-L-Met-Gly-L-His-L-Phe-L-Arg-L-Trp-L-Asp-L-Arg-L-Phe-R.sub.2 Iin whichR.sub.1 represents hydrogen or a lower aliphatic acyl (1-6 C) group andR.sub.2 represents the group --OH or --Gly--OH,as well as salts, esters and amides thereof.

Abstract: The present invention relates to novel psycho-pharmacological active peptides and peptide derivatives of the formula:A-R-L-Ser-R.sub.1 -L-Thr-L-Pro-L-Leu-L-Val-L-Thr-BwhereinR represents the amino acid residue L-Lys or L-Arg,R.sub.1 represents the amino acid residue L-Glu or L-Gln,B represents one of the following amino acid or peptide-radicals:L-Leu-OH, (.alpha.-dehydro)Leu-OHD-Leu-OHL-Leu-L-Phe-OHL-Leu-L-Phe-L-Lys-OHL-MeLeu-OHor the radical ##STR1## and A represents one of the following radicals or residues: hydrogenH-L-GluZ.sub.1 -L-GluZ.sub.2 -L-Ser-L-Glu-H-Q.sub.1 -L-Thr-L-Ser-L-Glu-Q.sub.2 -L-Thr-L-Ser-L-Glu-Z.sub.3 -Q.sub.1 -L-Thr-L-Ser-L-Glu- orH.sub.2 N-ALK-CO-L-Phe-Q.sub.1 -L-Thr-L-Ser-L-Glu-in whichZ.sub.1 represents H-L-Ser, H-D-Ser, desamino-Ser, 2,3-dihydroxy propanoyl or H.sub.2 N-ALK-CO-,Z.sub.2 represents H-L-Thr, H-D-Thr, desamino-Thr, 2,3-dihydroxybutanoyl or H.sub.2 N-ALK-CO;Q.sub.1 represents L-Met, L-Met(O), L-Met (O.sub.2) or L-LeuQ.sub.

Abstract: Novel and biologically useful peptides of the formula: A.sub.1 -A.sub.2 -L-Phe-X-L-Thr-L-Ser-R.sub.1 -Y-L-Ser-R.sub.2 -L-Thr-L-Pro-L-Leu-L-Val-L-Thr-B are disclosed (together with pharmaceutical compositions comprising a pharmaceutically effective amount of same) wherein:(a) A.sub.1 and A.sub.2 each represent an aminoacid residue of the formula H.sub.2 N-ALK-CO-, where ALK is an alkylidene group with 1 to 6 carbon atoms inclusively;(b) X is an amino-acid residue selected from the group consisting of L-Met, L-Met(O), L-Met(O.sub.2) and L-Leu;(c) R.sub.1 and R.sub.

Abstract: Novel peptides of the formula ##STR1## are disclosed (together with pharmaceutical compositions comprising a pharmaceutically effective amount of same) wherein X.sub.1 and X.sub.2 represent an hydroxy or amino group and B represents:(1) hydroxy or(2) an amino-acid residue selected from the group consisting of L-Asp-OH, L-Asn-OH, L-Glu-OH, L-Gln-OH, L-Ser-OH, or HN-A-COOH, wherein A is an alkylidene group from 1 to 6 carbon atoms;or a functional derivative thereof.These peptides have psychopharmacological properties; they are suitable for the treatment of certain mental disorders in which stimulation of brain function is desired, such as for the treatment of senility or amnesia.

Abstract: The new hypocalcaemically active peptides of formula I ##STR1## and corresponding compounds in which one or more of the asparagine and glutamic acid radicals are replaced by the aspartic acid or glutamic acid radical and/or the aspartic acid radical is replaced by the asparagine radical, their dimers, especially those in which 2 identical peptide sequences (1-32 and 1'-32') are joined in an anti-parallel arrangement via the cysteine radicals 1,7' and 7,1' by means of a disulfide bond, and derivatives are useful as hypocalcaemic agents and are prepared by splitting off groups protecting at least one amino or one carboxyl group or oxidizing the corresponding sulfides to the disulfides or condensing together adequate peptides.

Abstract: Biologically active novel peptide compounds are disclosed of the formulaA-L-B-D-Lys-L-Phe-Gly-(L or D)Lys-L-Pro-L-Val-Gly-L-Lys-L-Lys-Xor a pharmaceutically acceptable non-toxic functional derivative thereof; A is a N-terminal chain prolongation selected from the group consisting of (1) hydrogen and (2) N-acyl radicals derived from (a) alkyl carboxylic acids having from one to about six carbons, (b) aralkyl carboxylic acids having from seven to about ten carbons, (c) amino acids, (d) peptides, (e) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of the amino acids, and (f) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of the peptides; B is an amino-acid residue selected from the group consisting of Phe, Trp, Tyr, and --NH--CHR.sub.1 --CO--, wherein R.sub.1 is hydrogen or alkyl from one to about six carbons; and X is a member selected from the group consisting of hydroxy, esterified hydroxy radicals, unsubstituted amino radicals and substituted amino radicals.